Dr. Cao’s research focuses on the molecular mechanisms and therapeutic interventions for liver diseases, particularly drug induced liver injury (DILI), metabolic dysfunction associated steatotic liver disease (MASLD/MASH), and alcoholic hepatitis (AH). His work integrates target discovery, mechanistic dissection, and natural product based drug development.
University of Kansas Medical Center
Kansas City, Kansas, USA
Department of Pharmacology, Toxicology and Therapeutics
Huazhong University of Science and Technology
Wuhan, Hubei, China
Department of Pharmacy